CD14 — CD14 Molecule

CD14 — CD14 Molecule

Overview

CD14 is a gene located on chromosome 5q31.3 that encodes the CD14 protein, a critical co-receptor for Toll-like receptor 4 (TLR4) involved in innate immune responses to bacterial lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs)[@ziegler1988]. CD14 is expressed primarily on monocytes, macrophages, neutrophils, and microglial cells in the brain, where it plays a pivotal role in mediating neuroinflammatory processes that contribute to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS)[@liu2017].

The CD14 protein exists in two primary forms: membrane-bound CD14 (mCD14) expressed on the surface of myeloid cells, and soluble CD14 (sCD14) shed from the cell surface or produced by alternative splicing. Both forms participate in pattern recognition and immune signaling, though membrane-bound CD14 is primarily responsible for cellular activation in response to LPS and other ligands[@haziot1996].

Gene Information

CD14 — CD14 Molecule

Overview

CD14 is a gene located on chromosome 5q31.3 that encodes the CD14 protein, a critical co-receptor for Toll-like receptor 4 (TLR4) involved in innate immune responses to bacterial lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs)[@ziegler1988]. CD14 is expressed primarily on monocytes, macrophages, neutrophils, and microglial cells in the brain, where it plays a pivotal role in mediating neuroinflammatory processes that contribute to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS)[@liu2017].

The CD14 protein exists in two primary forms: membrane-bound CD14 (mCD14) expressed on the surface of myeloid cells, and soluble CD14 (sCD14) shed from the cell surface or produced by alternative splicing. Both forms participate in pattern recognition and immune signaling, though membrane-bound CD14 is primarily responsible for cellular activation in response to LPS and other ligands[@haziot1996].

Gene Information

<div class="infobox infobox-gene">
| Property | Value |
|---------|-------|
| Gene Symbol | CD14 |
| Full Name | CD14 Molecule |
| Chromosomal Location | 5q31.3 |
| NCBI Gene ID | [929](https://www.ncbi.nlm.nih.gov/gene/929) |
| Ensembl ID | [ENSG00000144891](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144891) |
| OMIM | [158120](https://omim.org/entry/158120) |
| UniProt ID | [P08571](https://www.uniprot.org/uniprot/P08571) |
| Protein Class | Pattern Recognition Receptor (PRR) |
| Expression | Monocytes, Macrophages, Neutrophils, Microglia |
| Gene Length | 2,379 bp (coding sequence) |
| Protein Length | 382 amino acids |
| Molecular Weight | ~40 kDa (glycosylated) |
| Subcellular Location | Cell membrane, secreted |
</div>

Protein Structure

The CD14 protein is a leucine-rich repeat (LRR) pattern recognition receptor with distinct structural features:

Extracellular Domain: The N-terminal portion contains multiple leucine-rich repeats (LRRs) that mediate pattern recognition. These LRRs form a horseshoe-shaped structure ideal for binding various pathogen-associated molecular patterns. The protein is heavily glycosylated, with N-linked glycosylation sites important for proper folding and function.

Membrane Anchoring: CD14 is attached to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor at its C-terminus. This allows for clustering in lipid rafts and facilitates interaction with TLR4/MD2 complexes. The GPI anchor enables rapid redistribution to phagocytic cups during particle engulfment.

Soluble Form: Soluble CD14 (sCD14) is generated through proteolytic cleavage by matrix metalloproteinases (MMPs) or through alternative splicing. sCD14 retains the ability to bind LPS and can transfer it to TLR4, but typically triggers less robust signaling due to the lack of membrane-associated clustering.

Normal Function

Innate Immune Recognition

CD14 functions as a crucial pattern recognition receptor in the innate immune system. Its primary roles include:

LPS Recognition: CD14 acts as the primary receptor for bacterial lipopolysaccharide (LPS), the major component of Gram-negative bacterial cell walls. CD14 facilitates the transfer of LPS to the TLR4/MD2 receptor complex, initiating downstream signaling cascades that lead to NF-κB activation and pro-inflammatory cytokine production[@haziot1996]. The binding affinity for LPS is in the nanomolar range, making CD14 one of the highest-affinity LPS receptors known.

Pattern Recognition: Beyond LPS, CD14 recognizes a broad range of PAMPs including:

• Lipoteichoic acid from Gram-positive bacteria
• Bacterial lipoproteins
• Fungal β-glucans
• Viral dsRNA
• Damage-associated molecular patterns (DAMPs) such as HMGB1 and heat shock proteins
• Amyloid-beta aggregates
• Alpha-synuclein fibrils

• Activation of NF-κB and AP-1 transcription factors
• Production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8)
• Upregulation of co-stimulatory molecules (CD80, CD86, MHC class II)
• Enhanced phagocytic activity
• Reactive oxygen species (ROS) generation
• Type I interferon production in some cell types

Soluble CD14 (sCD14)

Soluble CD14 serves distinct functions:

• Enables LPS responsiveness in cells lacking membrane CD14 (endothelial cells, epithelial cells)
• Acts as a decoy receptor, potentially dampening inflammatory responses
• Levels increase during systemic inflammation and serve as a biomarker
• Mediates LPS-induced cytokine production in endothelial cells
• Regulates TLR4 signaling by presenting ligand to the receptor complex

CD14 in Brain Immune Cells

Within the central nervous system, CD14 is expressed primarily on microglia, the resident immune cells of the brain. Microglial CD14 plays unique roles in brain homeostasis:

Surveillance: Resting microglia express CD14 at low levels and use it to survey the environment for danger signals. CD14 enables rapid detection of pathogens or endogenous damage signals.

Phagocytosis: CD14 facilitates the recognition and engulfment of cellular debris, amyloid deposits, and pathogens. This function is critical for maintaining brain homeostasis and clearing pathological protein aggregates.

Neuroinflammation: Upon activation, microglial CD14 expression increases substantially, leading to enhanced pro-inflammatory cytokine production. This can be protective when transient but becomes pathological when chronic.

Role in Neurodegenerative Diseases

Alzheimer's Disease

CD14 plays a significant role in AD pathogenesis through multiple mechanisms:

Amyloid-Beta Mediated Inflammation: CD14 on microglia recognizes amyloid-beta (Aβ) aggregates as endogenous danger signals. This interaction triggers microglial activation, leading to the release of pro-inflammatory cytokines, reactive oxygen species, and nitric oxide that contribute to synaptic loss and neuronal death[@zhang2018]. Studies have demonstrated that CD14 deficiency in mouse models results in reduced Aβ-induced neuroinflammation and improved cognitive function.

The interaction between Aβ and CD14 is mediated through the N-terminal LRR domain, which can bind Aβ fibrils with moderate affinity. This binding is distinct from LPS recognition and involves different structural elements of the CD14 protein.

TLR4/CD14 Signaling: The TLR4/CD14 complex is a primary pathway through which Aβ activates innate immune responses in the brain[@kwon2019]. This signaling contributes to:

• Chronic neuroinflammation
• Dysregulation of cholinergic signaling
• Impaired clearance of Aβ deposits
• Acceleration of tau pathology
• Synaptic dysfunction and loss
• Memory impairment

Genetic Associations: Several studies have identified CD14 polymorphisms associated with AD risk. The CD14 rs2569190 promoter polymorphism (-260C>T) has been linked to altered CD14 expression and modified AD risk in population studies[@zhang2019][@wood2023].

The T allele of rs2569190 is associated with increased CD14 expression and has been linked to:

• Higher risk of late-onset AD in some populations
• Increased susceptibility to sporadic AD
• Altered microglial activation patterns
• Modified response to anti-inflammatory therapies

CSF sCD14 levels show:

• Significant elevation in AD patients compared to controls
• Correlation with CSF Aβ42 levels (inverse relationship)
• Association with tau protein levels
• Potential for monitoring disease progression
• Utility in differentiating AD from other dementias (limited)

Parkinson's Disease

In Parkinson's disease, CD14 contributes to neuroinflammation and dopaminergic neurodegeneration:

LPS-Induced Model: In models of LPS-induced dopaminergic degeneration, CD14 mediates microglial activation and subsequent loss of substantia nigra pars compacta neurons[@lee2020]. CD14-deficient mice show resistance to LPS-induced neurotoxicity, highlighting its critical role.

The LPS model is particularly relevant to PD because:

• LPS can enter the brain through multiple routes
• Chronic peripheral inflammation can trigger microglial activation
• LPS exposure mimics the neuroinflammation seen in PD patients

This interaction involves recognition of the fibrillar form of alpha-synuclein by CD14's pattern recognition domains. Binding triggers:

• NF-κB activation
• Pro-inflammatory cytokine release
• Increased oxidative stress
• Impaired autophagy
• Accelerated protein aggregation

The MPTP model reveals that:

• CD14 is upregulated in substantia nigra of PD models
• Microglial CD14 contributes to progressive neuron loss
• Targeting CD14 may provide neuroprotective effects

Multiple Sclerosis

CD14 is involved in the neuroinflammatory processes characteristic of multiple sclerosis:

Blood-Brain Barrier Breakdown: CD14-mediated signaling contributes to endothelial cell activation and blood-brain barrier (BBB) disruption in MS[@park2022].

The mechanisms include:

• Production of matrix metalloproteinases (MMPs)
• Increased expression of adhesion molecules (VCAM-1, ICAM-1)
• Enhanced leukocyte trafficking into the CNS
• Cytokine-induced endothelial dysfunction

Lesion characterization shows:

• High density of CD14+ microglia in active lesions
• Correlation between CD14 expression and demyelination activity
• Association with axonal transection markers
• Modulation by disease-modifying therapies

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): CD14-mediated microglial activation contributes to motor neuron injury in ALS models. Studies show:

• Increased CD14 expression in spinal cord microglia
• Correlation with disease progression
• Potential for therapeutic intervention

Frontotemporal Dementia: Elevated CD14 expression has been observed in FTD brain tissue.

Huntington's Disease: CD14 polymorphisms may modify disease onset and progression.

Signaling Pathways

CD14 engages multiple downstream signaling pathways:

MyD88-Dependent Pathway

The MyD88-dependent pathway is the primary signaling route for CD14/TLR4 activation:

TRIF-Dependent Pathway

The TRIF-dependent pathway provides delayed and distinct responses:

Endocytosis-Dependent Signaling

CD14/TLR4 signaling can also occur through endocytosis:

Therapeutic Implications

CD14 as Therapeutic Target

Given its central role in neuroinflammation, CD14 represents a promising therapeutic target:

Blocking Antibodies: Anti-CD14 monoclonal antibodies have shown promise in preclinical models by reducing Aβ-induced microglial activation and improving cognitive function[@kim2021].

Antibody-based approaches offer:

• High specificity for CD14
• Potential for blood-brain barrier penetration
• Ability to block multiple CD14 ligands
• Long half-life in vivo

Current approaches include:

• TAK-242 (resatorvid): a TLR4 signaling inhibitor
• E5564 (eritoran): a TLR4 antagonist
• Synthetic TLR4 antagonists

Decoy Receptors: Soluble CD14 variants that act as decoys could potentially dampen excessive inflammation.

Sex-Specific Considerations

Recent research indicates that CD14 effects may be sex-specific, with males and females showing differential responses to CD14 modulation in AD pathogenesis[@yang2021]. This has implications for personalized therapeutic approaches.

Key differences include:

• Baseline CD14 expression levels differ by sex
• Hormonal modulation of CD14 signaling
• Sex-specific responses to CD14-targeted therapies
• Variable genetic associations by sex

Research Methods

Key experimental approaches for studying CD14 in neurodegeneration:

• Knockout mice: CD14-/- mice used to assess the role of CD14 in various models
• Conditional knockouts: Microglia-specific CD14 deletion using CX3CR1-Cre
• Cell culture: Primary microglia and neuronal co-cultures
• Flow cytometry: CD14 surface expression analysis
• ELISA: sCD14 levels in CSF and serum
• Western blot: CD14 protein expression
• qPCR: CD14 mRNA quantification
• Immunohistochemistry: CD14 localization in brain tissue
• CRISPR/Cas9: Genetic manipulation of CD14 in cell lines

Conclusion

CD14 serves as a critical interface between pattern recognition and neuroinflammatory responses in the brain. Its involvement in multiple neurodegenerative diseases makes it an attractive therapeutic target. However, the dual nature of CD14-mediated inflammation—protective in acute responses but pathological in chronic activation—presents a therapeutic challenge. Further research is needed to develop strategies that selectively modulate CD14 signaling without compromising essential immune functions.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CD14 — CD14 Molecule discovered through SciDEX knowledge graph analysis: